TEDOR Pharma, Inc. plans to expand its current multi-purpose manufacturing capacity at its facility in Cumberland, Rhode Island.
Several multi-purpose cGMP bays and additional large scale manufacturing equipment are to be installed in the capacity. The new facilities will undergo validation and cGMP qualification prior to its operational startup slated for Q1 2017.
This leads to the enhancement of the large scale manufacturing capabilities of the Cumberland facility, which supports client’s development projects from R&D through to large scale commercial manufacturing.
The multi-million dollar investment facility is adjacent to the 250 acres CVS corporate campus. This manufacturing addition and investment helps to increase the size of the facility. This helps to create expanded capacity and capabilities that are needed for our drug development programs.
The expansion is phase one of an ongoing strategic effort to invest in solid oral dose for both immediate release and modified release formulations that include schedule II controlled substances.
|Name||TEDOR Pharma, Inc.|
|Location||Cumberland, Rhode Island|
|Parties Involved||TEDOR Pharma, Inc.|